SARS-CoV-2肺炎の重症化に好中球のRegnase-1タンパク質が寄与~好中球のRegnase-1を標的とした治療の可能性~

ad

2026-02-19 京都大学

京都大学を中心とする研究グループは、炎症制御因子Regnase-1がSARS-CoV-2肺炎の重症化に関与することを明らかにした。Regnase-1量が半減したマウスでは、マウス適応型SARS-CoV-2感染後の体重減少や致死率が低下し、肺炎も軽症化。特に好中球に発現するRegnase-1がI型インターフェロン応答を過剰に誘導し、病態悪化に寄与することが示唆された。炎症抑制因子と考えられていたRegnase-1が、感染状況下では逆に重症化に関与する可能性を示す成果で、好中球のRegnase-1を標的とした新たな治療戦略が期待される。論文は『PLOS Pathogens』に掲載。

SARS-CoV-2肺炎の重症化に好中球のRegnase-1タンパク質が寄与~好中球のRegnase-1を標的とした治療の可能性~
好中球でRegnase-1が過剰なI型インターフェロン応答に関わりSARS-CoV-2肺炎が重症化する。

<関連情報>

Regnase-1 を介した好中球の調節が SARS-CoV-2 肺炎を抑制する Regnase-1-mediated regulation of neutrophils modulates SARS-CoV-2 pneumonia

Keiko Yasuda,Junichi Aoki,Kotaro Tanaka,Shintaro Shichinohe,Chikako Ono,Alexis Vandenbon,Daiya Ohara,Yukiko Muramoto,Songling Li,Daisuke Motooka,Hitomi Watanabe,Keiji Hirota,Gen Kondoh, [ … ],Osamu Takeuchi
PLOS Pathogens
  Published: February 9, 2026
DOI:https://doi.org/10.1371/journal.ppat.1013969

Abstract

The innate immune response to viral infection needs to be tightly regulated to ensure effective pathogen clearance while avoiding excessive immune activation. During SARS-CoV-2 infection, however, the immune system often fails to elicit appropriate responses, resulting in cytokine-release syndrome in patients with COVID-19. In this study, we show that reduced expression of Regnase-1, an RNase that negatively regulates immune cell activation, confers resistance to infection with the mouse-adapted SARS-CoV-2 MA10 strain. In Regnase-1+/– mice, altered neutrophil function contributed to the amelioration of MA10-induced pneumonia. Single-cell RNA sequencing of lung tissue during MA10 infection revealed four distinct neutrophil subsets, and among these, a subset characterized by an interferon-stimulated gene (ISG) signature was decreased in Regnase-1+/– mice. Furthermore, Regnase-1+/– neutrophils exhibited reduced ISG expression without corresponding changes in proinflammatory gene expression. Regnase-1 was found to repress the expression of Tsc22d3, a gene involved in the negative regulation of interferon responses, through its 3′ untranslated region. Collectively, these findings suggest that Regnase-1 attenuates resistance to SARS-CoV-2 MA10 infection by promoting excessive interferon responses in neutrophils.

Author summary

Significant progress has been made in understanding the pathophysiology of SARS-CoV-2 infection. However, the mechanisms by which innate immune cells are activated to eliminate viruses while restraining hyperinflammation remain unclear. Antiviral innate immune responses are regulated by multiple checkpoints that balance effective inflammatory activity with the prevention of cytokine release syndrome. In this study, we demonstrate that the expression level of Regnase-1, a posttranscriptional regulator of immune cells, determines resistance to infection with the mouse-adapted SARS-CoV-2 MA10 strain. Reduced Regnase-1 expression in neutrophils significantly enhances resistance to viral infection. A decreased representation of a neutrophil subset characterized by a robust interferon-stimulated gene signature is associated with the attenuation of excessive inflammation. These excessive interferon responses may contribute to increased mortality from a lethal dose of the MA10 strain. Regnase-1 suppresses the expression of Tsc22d3, a negative regulator of IFN signaling. This implicates Regnase-1 in the dysregulation of immune reactions during infection. Our findings identify Regnase-1 as a novel regulator of neutrophil function and antiviral immunity, which modulates disease severity and pulmonary inflammation.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました